Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Itacitinib adipate by Incyte for Graft Versus Host Disease (GVHD): Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase III for Graft Versus Host Disease (GVHD). According...
Itacitinib adipate by Incyte for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to...
Itacitinib adipate by Incyte for Myelodysplastic Syndrome: Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Myelodysplastic Syndrome. According to GlobalData, Phase...
Itacitinib adipate by Incyte for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
Itacitinib adipate by Incyte for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
Itacitinib adipate by Incyte for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...
Itacitinib adipate by Incyte for Non-Hodgkin Lymphoma: Likelihood of Approval
Itacitinib adipate is under clinical development by Incyte and currently in Phase I for Non-Hodgkin Lymphoma. According to GlobalData, Phase...